Microvesicle phenotypes are associated with transfusion requirements and mortality in subjects with severe injuries

Nena Matijevic1,2, Yao-Wei W Wang3, John B Holcomb1,3

  • 1Department of Surgery, The University of Texas Health Science Center at Houston, Houston, TX, USA.

Abstract

Insights

Microvesicle (MV) phenotypes change after severe injury, impacting transfusion needs and survival. Altered MV levels and types are linked to mortality risk in trauma patients.

Area of Science:

  • Trauma and Emergency Medicine
  • Vascular Biology
  • Coagulation and Hemostasis

Background:

  • Severe injury causes significant bleeding and mortality.
  • Injury triggers cellular activation and the release of extracellular vesicles, including procoagulant microvesicles (MVs).
  • The specific role of MVs in survival following severe trauma remains unclear.

Purpose of the Study:

  • To investigate the association between microvesicle (MV) phenotypes and transfusion requirements.
  • To determine if MV alterations correlate with outcomes in patients with severe injuries.
  • To explore the relationship between MV levels, cellular origin, and 24-hour mortality.

Main Methods:

  • A single-center study analyzed plasma samples from 169 major trauma patients and 26 healthy controls.
  • Flow cytometry was used to quantify MV counts and cellular origins (platelet, erythrocyte, leukocyte, endothelial, tissue factor, annexin V).
  • Samples were collected on admission and post-resuscitation, with 24-hour mortality as the primary outcome measure.

Main Results:

  • Patients exhibited distinct MV profiles compared to controls, with elevated endothelial MVs (EMVs) in both survivors and non-survivors.
  • Lower admission levels of platelet-derived MVs (PMVs), annexin V MVs (AVMVs), erythrocyte MVs (RMVs), and tissue factor MVs (TF-MVs) were observed in non-survivors.
  • Decreased AVMV and PMV levels over time in non-survivors correlated with increased blood product transfusion requirements and higher 24-hour mortality.

Conclusions:

  • Severe injury leads to endothelial activation and significant alterations in MV phenotypes.
  • Specific MV phenotypes and their dynamic changes over time are associated with the need for blood products and 24-hour mortality in trauma patients.

Related Concept Videos

Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
15.7K
Blood Transfusion01:15

Blood Transfusion

Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
2.9K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.4K